These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12009282)

  • 1. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.
    Kashala O; Amador R; Valero MV; Moreno A; Barbosa A; Nickel B; Daubenberger CA; Guzman F; Pluschke G; Patarroyo ME
    Vaccine; 2002 May; 20(17-18):2263-77. PubMed ID: 12009282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune responses during a malaria vaccine trial in Tanzanian infants.
    Galindo CM; Acosta CJ; Schellenberg D; Aponte JJ; Roca A; Oettli A; Urassa H; Armstrong Schellenberg J; Kahigwa E; Ascaso C; Mshinda H; Lwilla F; Vidal J; Menendez C; Tanner M; Alonso PL
    Parasite Immunol; 2000 Sep; 22(9):437-43. PubMed ID: 10972850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.
    Pöltl-Frank F; Zurbriggen R; Helg A; Stuart F; Robinson J; Glück R; Pluschke G
    Clin Exp Immunol; 1999 Sep; 117(3):496-503. PubMed ID: 10469053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission.
    Teuscher T; Schellenberg JR; Bastos de Azevedo I; Hurt N; Smith T; Hayes R; Masanja H; Silva Y; Lopez MC; Kitua A
    Vaccine; 1994 Mar; 12(4):328-36. PubMed ID: 8178555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy trial of malaria vaccine SPf66 in Gambian infants.
    D'Alessandro U; Leach A; Drakeley CJ; Bennett S; Olaleye BO; Fegan GW; Jawara M; Langerock P; George MO; Targett GA
    Lancet; 1995 Aug; 346(8973):462-7. PubMed ID: 7637479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador.
    Sempértegui F; Estrella B; Moscoso J; Piedrahita L; Hernández D; Gaybor J; Naranjo P; Mancero O; Arias S; Bernal R
    Vaccine; 1994 Mar; 12(4):337-42. PubMed ID: 8178556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.
    Rosas JE; Hernández RM; Gascón AR; Igartua M; Guzman F; Patarroyo ME; Pedraz JL
    Vaccine; 2001 Aug; 19(31):4445-51. PubMed ID: 11483270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological responses of Gambian children to immunization with the malaria vaccine SPf66.
    Metzger WG; Haywood M; D'Alessandro U; Drakeley CJ; Weiss H; Bojang K; Targett GA; Greenwood BM
    Parasite Immunol; 1999 Jul; 21(7):335-40. PubMed ID: 10417667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand.
    Migasena S; Heppner DG; Kyle DE; Chongsuphajaisiddhi T; Gordon DM; Suntharasamai P; Permpanich B; Brockman A; Pitiuttutham P; Wongsrichanalai C; Srisuriya P; Phonrat B; Pavanand K; Viravan C; Ballou WR
    Acta Trop; 1997 Sep; 67(3):215-27. PubMed ID: 9241386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate.
    Gozar MM; Muratova O; Keister DB; Kensil CR; Price VL; Kaslow DC
    Exp Parasitol; 2001 Feb; 97(2):61-9. PubMed ID: 11281702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malaria vaccine trials: the missing qualitative data.
    Ferreira M
    Immunol Cell Biol; 1996 Aug; 74(4):301-5. PubMed ID: 8872178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune response to the anti-malaria vaccine SPf66 in the Colombian Atrato River region.
    Lopera TM; Restrepo M; Blair S; García HI
    Mem Inst Oswaldo Cruz; 1998; 93(4):495-500. PubMed ID: 9711340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity.
    Amador R; Moreno A; Valero V; Murillo L; Mora AL; Rojas M; Rocha C; Salcedo M; Guzman F; Espejo F
    Vaccine; 1992; 10(3):179-84. PubMed ID: 1557934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.
    Moreno CA; Rodriguez R; Oliveira GA; Ferreira V; Nussenzweig RS; Moya Castro ZR; Calvo-Calle JM; Nardin E
    Vaccine; 1999 Aug; 18(1-2):89-99. PubMed ID: 10501239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
    Dejon-Agobe JC; Ateba-Ngoa U; Lalremruata A; Homoet A; Engelhorn J; Nouatin OP; Edoa JR; Fernandes JF; Esen M; Mouwenda YD; Betouke Ongwe EM; Massinga-Loembe M; Hoffman SL; Sim BKL; Theisen M; Kremsner PG; Adegnika AA; Lell B; Mordmüller B
    Clin Infect Dis; 2019 Sep; 69(8):1377-1384. PubMed ID: 30561539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of malaria vaccines: SPf66--what next?
    Tanner M; Alonso PL
    Schweiz Med Wochenschr; 1996 Jul; 126(27-28):1210-5. PubMed ID: 8766632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines for preventing malaria.
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2003; (1):CD000129. PubMed ID: 12535387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.